In breast cancer, the upregulation of FOXA1 leads to the reprogramming of estrogen receptor function, contributing to endocrine resistance and the promotion of metastasis in ER-positive tumors through a High-FOXA1/ER-dependent secretory mechanism [40]. Here, ESR1 is linked to breast carcinoma.